1. Home
  2. SRPT vs GCMGW Comparison

SRPT vs GCMGW Comparison

Compare SRPT & GCMGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRPT
  • GCMGW
  • Stock Information
  • Founded
  • SRPT 1980
  • GCMGW 1971
  • Country
  • SRPT United States
  • GCMGW United States
  • Employees
  • SRPT N/A
  • GCMGW 549
  • Industry
  • SRPT Biotechnology: Pharmaceutical Preparations
  • GCMGW Finance/Investors Services
  • Sector
  • SRPT Health Care
  • GCMGW Finance
  • Exchange
  • SRPT Nasdaq
  • GCMGW Nasdaq
  • Market Cap
  • SRPT 1.7B
  • GCMGW N/A
  • IPO Year
  • SRPT 1997
  • GCMGW N/A
  • Fundamental
  • Price
  • SRPT $18.19
  • GCMGW N/A
  • Analyst Decision
  • SRPT Buy
  • GCMGW
  • Analyst Count
  • SRPT 25
  • GCMGW 0
  • Target Price
  • SRPT $64.00
  • GCMGW N/A
  • AVG Volume (30 Days)
  • SRPT 7.9M
  • GCMGW 62.4K
  • Earning Date
  • SRPT 08-06-2025
  • GCMGW 02-13-2025
  • Dividend Yield
  • SRPT N/A
  • GCMGW N/A
  • EPS Growth
  • SRPT N/A
  • GCMGW N/A
  • EPS
  • SRPT N/A
  • GCMGW 0.03
  • Revenue
  • SRPT $2,233,371,000.00
  • GCMGW $514,011,999.00
  • Revenue This Year
  • SRPT $26.87
  • GCMGW N/A
  • Revenue Next Year
  • SRPT $3.15
  • GCMGW N/A
  • P/E Ratio
  • SRPT N/A
  • GCMGW $33.02
  • Revenue Growth
  • SRPT 59.15
  • GCMGW 15.79
  • 52 Week Low
  • SRPT $16.88
  • GCMGW $2.28
  • 52 Week High
  • SRPT $155.95
  • GCMGW $2.50
  • Technical
  • Relative Strength Index (RSI)
  • SRPT 23.09
  • GCMGW N/A
  • Support Level
  • SRPT $16.88
  • GCMGW N/A
  • Resistance Level
  • SRPT $18.62
  • GCMGW N/A
  • Average True Range (ATR)
  • SRPT 1.40
  • GCMGW 0.00
  • MACD
  • SRPT 0.09
  • GCMGW 0.00
  • Stochastic Oscillator
  • SRPT 6.41
  • GCMGW 0.00

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

About GCMGW GCM Grosvenor Inc.

GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. Company invest maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.

Share on Social Networks: